Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Tiziana Life Sciences Ltd (NQ: TLSA ) 0.9100 +0.0120 (+1.34%) Streaming Delayed Price Updated: 3:59 PM EST, Nov 7, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Tiziana Life Sciences Ltd < Previous 1 2 3 4 5 6 7 8 Next > Tiziana Life Sciences reveals "exciting" clinical data from latest MS trial October 17, 2023 Tiziana Life Sciences Ltd (NASDAQ:TLSA) chief medical officer and chief operating officer Matthew Davis speaks to Thomas Warner from Proactive after the clinical-stage biopharmaceutical company... Via TheNewswire.com Tiziana Life Sciences reports six-month PET scan results for MS patients October 16, 2023 --News Direct-- Via News Direct Tiziana Life Sciences reports six-month PET scan results for MS patients October 16, 2023 Tiziana Life Sciences Ltd (NASDAQ:TLSA) chief medical officer and chief operating officer Matthew Davis speaks to Thomas Warner from Proactive after the clinical-stage biopharmaceutical company... Via TheNewswire.com Tiziana Life Sciences Announces Positive Six-Month Clinical Results in Multiple Sclerosis Patients Treated with Intranasal Foralumab October 16, 2023 From Tiziana Life Sciences Ltd. Via GlobeNewswire Tiziana to Announce Six-Month Human Safety and Biomarker Data at the ECTRIMS Annual Congress, Following-Up from Positive Outcomes Data Presented in June October 13, 2023 --News Direct-- Via News Direct Exposures Product Safety Tiziana Announces Positive Qualitative Six-Month PET Scan Results With Intranasal Foralumab Treating Multiple Sclerosis Patients Diagnosed With Non-Active Secondary Progressive MS (na-SPMS) October 13, 2023 From Tiziana Life Sciences Ltd. Via GlobeNewswire Tiziana To Announce Six-Month Human Safety And Biomarker Data At The ECTRIMS Annual Congress, Following-Up From Positive Outcomes Data Presented In June October 12, 2023 Tiziana (NASDAQ: TLSA) is following up with anticipated human data and announced the acceptance of a late-breaking poster at the 39th Congress of the Europea Via Benzinga Tiziana Announces Presentation of Six-Month Safety and Biomarker Data for Intranasal Foralumab in Patients with Non-Active Secondary Progressive Multiple Sclerosis (na-SPMS) at the ECTRIMS Annual Congress October 11, 2023 From Tiziana Life Sciences Ltd. Via GlobeNewswire Tiziana Advances Phase 2 Site Selection for Its Lead Clinical Program in Non-Active Secondary Progressive Multiple Sclerosis (SPMS) and The Company Prepares for Six-Month Clinical Data Update October 05, 2023 --News Direct-- Via News Direct Cathie Wood Sells $25 Million In Tesla Stock As TSLA Flashes Aggressive Buy Signal October 05, 2023 Wood's Ark Invest unloaded nearly 100,000 TSLA shares Wednesday. Via Investor's Business Daily Tiziana Advances Phase 2 Site Selection For Its Lead Clinical Program In Non-Active Secondary Progressive Multiple Sclerosis (SPMS) And The Company Prepares For Six-Month Clinical Data Update October 04, 2023 Tiziana Life Sciences Ltd. (NASDAQ: TLSA) recently announced the Company has initiated site selection for its lead intranasal anti-CD3 monoclonal antibody drug c Via Benzinga Latest AI Quantum Computing News And Company Stock Performances YTD October 03, 2023 The global quantum computing market is expected to grow at a CAGR of 38.3% over the next 5 years which presents an incredible opportunity for investors so which AI quantum computing stocks are... Via Talk Markets Topics Artificial Intelligence Exposures Artificial Intelligence Tiziana Life Sciences Prepares To Advance Lead Intranasal Foralumab Program In First-Of-Its-Kind Phase 2a Clinical Trial for Non-Active SPMS Patients September 27, 2023 Tiziana Life Sciences Ltd. (NASDAQ: TLSA) has taken a major step towards addressing Secondary Progressive Multiple Sclerosis (SPMS) by initiating Phase 2a clinical trials for its intranasal foralumab... Via Benzinga Tiziana Life Sciences Initiates Multi-Center Phase 2a Clinical Trial of Intranasal Foralumab for Non-Active Secondary Progressive Multiple Sclerosis September 26, 2023 From Tiziana Life Sciences Ltd. Via GlobeNewswire Cathie Wood Dumps 170,000 Tesla Shares This Week As TSLA Falls Harder Than The S&P 500 September 22, 2023 Wood continued selling Tesla shares as TSLA forged a new buy point. Via Investor's Business Daily Topics Stocks Exposures US Equities Tesla Cybertruck To Be Used For Oracle's Next-Gen Police Car September 20, 2023 Oracle Corp (NYSE: ORCL) co-founder and Executive Chairman Larry Ellison recently made a surprising reveal during his CloudWorld talk. Via Benzinga Tiziana Reveals Alzheimer's Research Milestone With PNAS Journal After FDA IND Green Light September 12, 2023 Tiziana Life Sciences Ltd. Via Benzinga Exposures Product Safety Tiziana Life Sciences' Alzheimer's treatment validated in new study September 12, 2023 --News Direct-- Via News Direct Tiziana Life Sciences' Alzheimer's treatment validated in new study September 12, 2023 Tiziana Life Sciences Ltd (NASDAQ:TLSA) chief medical officer and chief operating officer Matthew Davis speaks to Thomas Warner from Proactive after the clinical-stage biopharmaceutical company... Via TheNewswire.com Tiziana Life Sciences to Participate in the H.C. Wainwright 25th Annual Global Investment Conference September 08, 2023 From Tiziana Life Sciences Ltd. Via GlobeNewswire Upcoming Phase 2 Data Expected For Longeveron's (NASDAQ: LGVN) Drug For the $4+ Billion Alzheimer's Sector – What To Look For September 06, 2023 Longeveron (NASDAQ: LGVN), a clinical-stage biopharma developing potential treatments for age-related and life-threatening diseases, is expecting data from its phase 2a trial for its Lomecel-B™... Via Benzinga Study Validating MoA of Intranasal Foralumab in Alzheimer’s Disease Published in the Prestigious Journal PNAS, Following FDA IND Clearance September 06, 2023 From Tiziana Life Sciences Ltd. Via GlobeNewswire Tiziana Life Sciences Announces Appointment of William A. Clementi as Chief Development Officer August 23, 2023 From Tiziana Life Sciences Ltd. Via GlobeNewswire Tiziana Life Sciences Announces Foralumab Presentation by Dr. Howard Weiner at the Annual Meeting of the International Society of Neuroimmunology August 23, 2023 From Tiziana Life Sciences Ltd. Via GlobeNewswire Tiziana Life Sciences Announces Live Bloomberg TV Interview of Renowned Scientist Dr. Howard L. Weiner to Discuss FDA IND Clearance for Intranasal Foralumab in Alzheimer's Disease August 17, 2023 From Tiziana Life Sciences Ltd. Via GlobeNewswire Tiziana's Intranasal Foralumab For Alzheimer's Treatment Gets FDA Nod For Phase 2 Trials Under Brigham And Women's Hospital Supervision August 16, 2023 Tiziana Life Sciences Ltd. (NASDAQ: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced... Via Benzinga Exposures Product Safety Why PhenomeX Are Trading Lower By Around 20%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session August 15, 2023 Gainers Novo Integrated Sciences, Inc. (NASDAQ: NVOS) jumped 85.4% to $0.1267 after the company and Farm 7 Group announced a joint venture for Kenya Agricultural Cooperative Project. Via Benzinga 12 Health Care Stocks Moving In Tuesday's Intraday Session August 15, 2023 Via Benzinga Why Tiziana Life Sciences Stock (TLSA) Is Climbing August 15, 2023 Tiziana Life Sciences, Ltd (NASDAQ: TLSA) shares are trading higher Tuesday after the company announced that the FDA has cleared the Investigational New Drug (IND) application for intranasal foralumab... Via Benzinga Exposures Product Safety Tiziana Life Sciences gets FDA green light to investigate potential Alzheimer's treatment August 15, 2023 --News Direct-- Via News Direct Exposures Product Safety < Previous 1 2 3 4 5 6 7 8 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
